Coronary Artery DiseasePROTECTION-VINCT02996903
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
An observational study of Coronary Artery Disease and Cardiac Disease, run by LMU Klinikum at 4 sites in 4 countries.
Trial summary
The "Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017" (PROTECTION-VI) study is a prospective registry and investigator-initiated initiative without third-party funding, which will collect and analyze the radiation dose exposure of Cardiac Computed… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease, Cardiac Disease, Malignancy, Second
- How many people
- 4,502 participants
- Where
- 4 sitesin 4 countries
- Study dates
- 1 Mar 2017to 31 Dec 2017
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing Cardiac Computed Tomography Angiography (CCTA) in clinical routine.
Who may be able to join
- Patients with a clinical indication for CCTA in order to evaluate the coronary arteries or other cardiac structures
- Patients age > 18 years
- Signed informed consent (if required by local IRB)
Who cannot join
- Known allergy to contrast agent
Trial locations and contacts
4 sites in 4 countries.
4 sites in 4 countries
United States1 site
National Heart, Lung, and Blood Institute
Bethesda, Maryland, 20892-1061
Canada1 site
University of British Columbia, Department of Medical Imaging
Vancouver, British Columbia
Germany1 site
Ludwig-Maximilians-Universitaet Muenchen, Medizinische Klinik I
Munich, Bavaria, 808303
Israel1 site
Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine
Haifa
About this study
The "Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017" (PROTECTION-VI) study is a prospective registry and investigator-initiated initiative without third-party funding, which will collect and analyze the radiation dose exposure of Cardiac Computed Tomography Angiographic (CCTA) studies in current daily practice worldwide. Particularly, the study will assess the use of strategies for dose reduction during CCTA.
A decade ago, the multicentre observational PROTECTION-I study has revealed that the dose-length-product of CCTA ranges between 568 - 1259 mGy x cm with a median of 885 mGy x cm. This corresponds to an estimated effective dose of approximately 12 mSv. Since then a variety of techniques have been developed and enhanced in order to reduce radiation exposure during CCTA. Recent studies demonstrated feasibility of dramatically reduced effective radiation doses during CCTA (0,1 - 0,3 mSv). This has been executed in small cohorts of patients at scientific expert centers. However, it remains unclear, if such low-level radiation dose exposure may be achieved in clinical routine and if diagnostic image quality is maintained. In order to analyze the magnitude of radiation dose exposure of CCTA in today's clinical practice and the current use of dose-saving techniques, we designed the PROTECTION-VI study. Eventually, this study may contribute to further improving radiation dose exposure for patients undergoing CCTA.
Read the detailed description
Cardiac CT angiography (CCTA) has emerged to a powerful and commonly used diagnostic tool for the evaluation of coronary artery disease. Advantages of CCTA are its non-invasive approach, widespread availability and high negative predictive value to rule out coronary artery disease. However, radiation exposure during CCTA needs to be considered, due to the potential risk of malignancy induction.
A decade ago, the multicentre observational PROTECTION I study has revealed that the dose-length-product of CCTA ranges between 568-1259 mGy x cm with a median of 885 mGy x cm. This corresponds to an estimated effective dose of approximately 12 mSv. Furthermore, PROTECTION I demonstrated an up to 7-fold variation of radiation dose between different study sites implicating the large potential for dose reduction. Finally, significant differences have been detected in the radiation exposures between CT systems from different vendors and application of dose-saving algorithms, implying that approaches for dose reduction with respect to hardware and software have also been of relevance in 2007.
Since then a variety of techniques have been developed and enhanced in order to reduce radiation exposure during CCTA. Earlier, ECG-controlled tube current modulation has been accepted to reduce radiation dose and was therefore used in ECG-gated retrospective cardiac spiral scanning.
Another dose-saving technique is the reduction of tube potential from conventionally 120 kVp to 100 kVp in non-obese patients. In the PROTECTION II trial we demonstrated that diagnostic image quality is being maintained with a reduction of tube potential to 100 kVp while radiation exposure was significantly reduced by 31%.
Development of prospective ECG-gated axial (sequential) scanning allowed further dose reduction, due to administration of radiation only at the end of diastole. In the PROTECTION III trial we could demonstrate that diagnostic image quality is being maintained with prospective ECG-gated axial scanning in patients with stable and low heart rates while radiation exposure was reduced by 69% when compared to conventional spiral scanning with retrospective ECG gating. Using prospectively ECG-triggered high-pitch spiral CCTA with image acquisition during only one cardiac cycle, additional dosage may be saved when used in selected patients with low and stable heart rates. However, a scan strategy with an attempt of high-pitch scanning first is vulnerable to motion artefacts and bears the risk of repeated scanning.
In the PROTECTION IV trial we compared a scan strategy of high-pitch helical scanning first with a conventional scan first strategy. We could demonstrate maintenance of image quality using the strategy of high-pitch helical scanning first, while radiation exposure was reduced by 57 %, when compared to the conventional scan first strategy.
The introduction of iterative image reconstruction technique with advanced raw data processing let to improvement of image quality compared to traditional filtered back projection. This allowed additional dose saving during image acquisition. In the PROTECTION V trial we demonstrated the feasibility of combining iterative image reconstruction techniques with a reduction of tube currents by 30% leading to maintenance of diagnostic image quality while saving radiation dose linearly to tube current.
In summary, the four randomized clinical trials PROTECTION II-V demonstrated that different techniques for reducing radiation exposure during CCTA can be applied in clinical practice without compromising diagnostic image quality. The studies show that the different approaches can also be applied in combination and that these approaches can be used with different CT platforms from different CT vendors.
Recent studies demonstrated that the effective radiation dose for one CCTA scan may be reduced to 0,3 mSv15 or even below 0,1 mSv in a small amount of carefully selected patients. However, it remains unclear if such dramatically low dosages are being achieved and if diagnostic image quality is being maintained in clinical routine. In order to analyze the magnitude of radiation dose exposure during CCTA in today's clinical practice, we designed the international and multicentric PROTECTION VI study. We will assess the variation of radiation dose with respect to vendors, CT systems and study sites. Furthermore, we will evaluate the usage of dose saving strategies including the above-mentioned in daily practice and analyze their effect on diagnostic image quality. On the basis of the collected data, we will evaluate the potential use of additional dose savings for each site individually.
- Conditions
- Coronary Artery Disease, Cardiac Disease, Malignancy, Second
- Keywords
- Cardiac Computed Tomography (CT) Angiography (CCTA), coronary artery disease, malignancy induction, radiation dose, dose saving techniques, effective dose
- Medical subject headings
- Coronary Artery Disease, Heart Diseases, Neoplasms, Second Primary
What is being measured
The primary outcome is the main question the study is designed to answer.
Radiation dose estimates of cardiac CT angiographies in daily practice
Assessment after CT scan by radiologist or technical assistant, documented on questionnaire.
Measured: Baseline
Secondary outcomes (5)
Use of dose-saving strategies
Use of Low tube potential imaging, Low tube current imaging, Automated Exposure Control, ECG-controlled tube current modulation (dose pulsing), Iterative image reconstruction techniques and Scan protocols (Prospective ECG-triggered axial scanning technique, Prospective ECG-triggered high-pitch spiral acquisition) will be assessed in the Core Lab according to information given by the CT-examiner on a questionnaire.
Measured: Baseline
Assessment of CCTA image quality in relation to radiation dose
Assessment after CT scan by CT-examiner on questionnaire (qualitative) or in the Core Lab (quantitative).
Quantitative Assessment includes Signal intensity, Image noise, Contrast-to-noise ratio, Signal-to-noise ratio. Qualitative assessment of each coronary artery is performed using a 3-point grading scale including excellent, intermediate or non-diagnostic as documented on a provided questionnaire.
Measured: Baseline
Sufficient result of the first CCTA scan or need for repeated scans
According to information given by the CT-examiner on a questionnaire.
Measured: Baseline
Cardiac CT scan length and relationship between scan and heart length
Assessment in Core Lab after analysis of CT scans.
Measured: Baseline
Comparison of dose estimates between different continents, CT vendors and CT systems
Analysis done in the Core Lab according to information given by the CT-examiner on a questionnaire.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2016 (estimated)
- Study start1 Mar 2017
- Primary completion31 Oct 2017
- Study completion31 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 4,502 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- LMU Klinikum
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thomas Stocker, LMU Klinikum
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02996903
- Sponsor's protocol ID
- MUC I002-16
- Acronym
- PROTECTION-VI
- Status last verified
- May 2018
- First submitted
- 13 Dec 2016
- Last updated
- 15 May 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Stocker TJ, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, Deseive S, Heckner M, Bax JJ, Kitagawa K, Marques H, Schmermund A, Silva C, Mahmarian J, Kang JW, Grove EL, Lesser J, Massberg S, Hausleiter J. Application of Low Tube Potentials in CCTA: Results From the PROTECTION VI Study. JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):425-434. doi: 10.1016/j.jcmg.2019.03.030. Epub 2019 Jun 12.
PubMed 31202772
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
- ClinicalTrials.gov ID
- NCT02996903
- Acronym / sponsor ID
- PROTECTION-VI / MUC I002-16
- Conditions
- Coronary Artery Disease, Cardiac Disease, Malignancy, Second
- Keywords
- Cardiac Computed Tomography (CT) Angiography (CCTA), coronary artery disease, malignancy induction, radiation dose, dose saving techniques, effective dose
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,502 participants (actual)
- Lead sponsor
- LMU KlinikumUniversity, hospital or other
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 31 Oct 2017 (actual)
- Study completion
- 31 Dec 2017 (actual)
- First posted
- 19 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The "Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017" (PROTECTION-VI) study is a prospective registry and investigator-initiated initiative without third-party funding, which will collect and analyze the radiation dose exposure of Cardiac Computed Tomography Angiographic (CCTA) studies in current daily practice worldwide. Particularly, the study will assess the use of strategies for dose reduction during CCTA.
A decade ago, the multicentre observational PROTECTION-I study has revealed that the dose-length-product of CCTA ranges between 568 - 1259 mGy x cm with a median of 885 mGy x cm. This corresponds to an estimated effective dose of approximately 12 mSv. Since then a variety of techniques have been developed and enhanced in order to reduce radiation exposure during CCTA. Recent studies demonstrated feasibility of dramatically reduced effective radiation doses during CCTA (0,1 - 0,3 mSv). This has been executed in small cohorts of patients at scientific expert centers. However, it remains unclear, if such low-level radiation dose exposure may be achieved in clinical routine and if diagnostic image quality is maintained. In order to analyze the magnitude of radiation dose exposure of CCTA in today's clinical practice and the current use of dose-saving techniques, we designed the PROTECTION-VI study. Eventually, this study may contribute to further improving radiation dose exposure for patients undergoing CCTA.
Detailed description
Cardiac CT angiography (CCTA) has emerged to a powerful and commonly used diagnostic tool for the evaluation of coronary artery disease. Advantages of CCTA are its non-invasive approach, widespread availability and high negative predictive value to rule out coronary artery disease. However, radiation exposure during CCTA needs to be considered, due to the potential risk of malignancy induction.
A decade ago, the multicentre observational PROTECTION I study has revealed that the dose-length-product of CCTA ranges between 568-1259 mGy x cm with a median of 885 mGy x cm. This corresponds to an estimated effective dose of approximately 12 mSv. Furthermore, PROTECTION I demonstrated an up to 7-fold variation of radiation dose between different study sites implicating the large potential for dose reduction. Finally, significant differences have been detected in the radiation exposures between CT systems from different vendors and application of dose-saving algorithms, implying that approaches for dose reduction with respect to hardware and software have also been of relevance in 2007.
Since then a variety of techniques have been developed and enhanced in order to reduce radiation exposure during CCTA. Earlier, ECG-controlled tube current modulation has been accepted to reduce radiation dose and was therefore used in ECG-gated retrospective cardiac spiral scanning.
Another dose-saving technique is the reduction of tube potential from conventionally 120 kVp to 100 kVp in non-obese patients. In the PROTECTION II trial we demonstrated that diagnostic image quality is being maintained with a reduction of tube potential to 100 kVp while radiation exposure was significantly reduced by 31%.
Development of prospective ECG-gated axial (sequential) scanning allowed further dose reduction, due to administration of radiation only at the end of diastole. In the PROTECTION III trial we could demonstrate that diagnostic image quality is being maintained with prospective ECG-gated axial scanning in patients with stable and low heart rates while radiation exposure was reduced by 69% when compared to conventional spiral scanning with retrospective ECG gating. Using prospectively ECG-triggered high-pitch spiral CCTA with image acquisition during only one cardiac cycle, additional dosage may be saved when used in selected patients with low and stable heart rates. However, a scan strategy with an attempt of high-pitch scanning first is vulnerable to motion artefacts and bears the risk of repeated scanning.
In the PROTECTION IV trial we compared a scan strategy of high-pitch helical scanning first with a conventional scan first strategy. We could demonstrate maintenance of image quality using the strategy of high-pitch helical scanning first, while radiation exposure was reduced by 57 %, when compared to the conventional scan first strategy.
The introduction of iterative image reconstruction technique with advanced raw data processing let to improvement of image quality compared to traditional filtered back projection. This allowed additional dose saving during image acquisition. In the PROTECTION V trial we demonstrated the feasibility of combining iterative image reconstruction techniques with a reduction of tube currents by 30% leading to maintenance of diagnostic image quality while saving radiation dose linearly to tube current.
In summary, the four randomized clinical trials PROTECTION II-V demonstrated that different techniques for reducing radiation exposure during CCTA can be applied in clinical practice without compromising diagnostic image quality. The studies show that the different approaches can also be applied in combination and that these approaches can be used with different CT platforms from different CT vendors.
Recent studies demonstrated that the effective radiation dose for one CCTA scan may be reduced to 0,3 mSv15 or even below 0,1 mSv in a small amount of carefully selected patients. However, it remains unclear if such dramatically low dosages are being achieved and if diagnostic image quality is being maintained in clinical routine. In order to analyze the magnitude of radiation dose exposure during CCTA in today's clinical practice, we designed the international and multicentric PROTECTION VI study. We will assess the variation of radiation dose with respect to vendors, CT systems and study sites. Furthermore, we will evaluate the usage of dose saving strategies including the above-mentioned in daily practice and analyze their effect on diagnostic image quality. On the basis of the collected data, we will evaluate the potential use of additional dose savings for each site individually.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing Cardiac Computed Tomography Angiography (CCTA) in clinical routine.
Key inclusion criteria (3 listed)
- Patients with a clinical indication for CCTA in order to evaluate the coronary arteries or other cardiac structures
- Patients age > 18 years
- Signed informed consent (if required by local IRB)
Key exclusion criteria (1 listed)
- Known allergy to contrast agent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Radiation dose estimates of cardiac CT angiographies in daily practice
Time frame: Baseline
Assessment after CT scan by radiologist or technical assistant, documented on questionnaire.
5 secondary outcomes
Use of dose-saving strategies
Time frame: Baseline
Assessment of CCTA image quality in relation to radiation dose
Time frame: Baseline
Sufficient result of the first CCTA scan or need for repeated scans
Time frame: Baseline
Cardiac CT scan length and relationship between scan and heart length
Time frame: Baseline
Comparison of dose estimates between different continents, CT vendors and CT systems
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2018.
- Derived from this study: PubMed 31202772Stocker TJ, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, Deseive S, Heckner M, Bax JJ, Kitagawa K, Marques H, Schmermund A, Silva C, Mahmarian J, Kang JW, Grove EL, Lesser J, Massberg S, Hausleiter J. Application of Low Tube Potentials in CCTA: Results From the PROTECTION VI Study. JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):425-434. doi: 10.1016/j.jcmg.2019.03.030. Epub 2019 Jun 12.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Cardiac Disease, run by LMU Klinikum at 4 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States, Canada, Germany, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radiation dose estimates of cardiac CT angiographies in daily practice (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02996903, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2018.